Skip to content
OpenCapital
Get started

Vaxcyte, Inc. PCVX UNITED STATES — PP&E (Net)

Other geography segments

SWITZERLAND
$219.4M+24.2%

Similar metrics at other companies

Silicon Laboratories logo
SLABUnited States — PP&E (Net)
$105.86M-0.6%
Crocs logo
CROXUnited States — PP&E (Net)
$194.71M-5.1%
Synopsys logo
SNPSUNITED STATES — PP&E (Net)
$327.8M-2.2%
Medpace Holdings, Inc. logo
MEDPUnited States — PP&E (Net)
$83.9M+4.0%
Incyte logo
INCYUnited States — PP&E (Net)
$401.34M-14.5%
MSA
MSAUnited States — Property, Plant and Equipment, Net
$177.51M+10.4%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0×0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s united states — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s UNITED STATES — PP&E (net)?
Vaxcyte, Inc. (PCVX) reported UNITED STATES — PP&E (net) of $41.3M in Q1 2026.
How has Vaxcyte, Inc.'s UNITED STATES — PP&E (net) changed year-over-year?
Vaxcyte, Inc.'s UNITED STATES — PP&E (net) increased by 2.0% year-over-year, from $40.5M to $41.3M.
What does UNITED STATES — PP&E (net) mean?
This metric represents the net book value of tangible long-term assets located within the United States, including laboratory equipment, manufacturing facilities, and leasehold improvements. It reflects the company's physical infrastructure investment required to support research, development, and clinical trial operations in its primary geographic market. Monitoring this balance helps investors assess the scale of capital expenditure dedicated to domestic operational capacity.